



Financial Tear Sheet

Corporate Profile

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

Stock Information

EBS (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$53.75
Change (%)	▲ 1.67 (3.21%)
Volume	589,344
52 Week Low	\$27.94
Market Cap	\$2,660,335,395
Rolling EPS	1.65
PE Ratio	31.4854
Shares Outstanding	49,494,612

Data as of 03/20/18 4:00 p.m. ET



Recent Headlines & Events

02/28/18

Emergent BioSolutions Awarded One-Year CDC Contract Valued at \$26 Million for Vaccinia Immune Globulin Program

02/26/18

Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus

02/22/18

Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results

There are currently no events scheduled.

SEC Filings

Filing Date	Form
03/13/18	4
03/13/18	4
03/13/18	4
03/13/18	4

Data provided by Nasdaq. Minimum 15 minutes delayed.

Primary IR Contact

Robert G. Burrows

Vice President,
Investor Relations

Emergent BioSolutions Inc.

Phone: (240) 631 3280

Fax: (240) 413-1917

E-mail: burrowsr@ebsi.com